SONN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
Current Price	$0.468
Today's Volume	2.64M
Average Volume	2.98M
Market Cap	12.86M
EPS	$-4.37
P/E	-0.110
ATR14	$0.0460 (9.91%)

Volume Correlation

Long: 0.72 (moderate)

Short: 0.26 (neutral)

Signal:(51) Neutral

Sonnet Biotherapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sonnet Biotherapeutics Correlation - Currency/Commodity

0.00
( neutral )

-0.13
( neutral )

0.00
( neutral )

0.05
( neutral )

Sonnet Biotherapeutics Financials

Annual 2022
Revenue: $349 943
Gross Profit: $0 (0.00%)
EPS: $-6.84

Q2 2023
Revenue: $36 445.00
Gross Profit: $36 445.00 (100.00%)
EPS: $-0.340

Q1 2023
Revenue: $37 255.00
Gross Profit: $37 255.00 (100.00%)
EPS: $-0.790

Q4 2022
Revenue: $62 753.00
Gross Profit: $0 (0.00%)
EPS: $-1.710

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.